{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:08:13Z","timestamp":1780546093577,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,3]]},"DOI":"10.7759\/cureus.110202","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T03:32:41Z","timestamp":1780543961000},"source":"Crossref","is-referenced-by-count":0,"title":["Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors as Therapy for Hidradenitis Suppurativa and Other Inflammatory Skin Diseases: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Declan C","family":"McCann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalia G","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey N","family":"Mayrovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis","volume":"82","author":"Goldburg SR","year":"2020","unstructured":"Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020, 82:1045-58. 10.1016\/j.jaad.2019.08.090","journal-title":"J Am Acad Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.013","article-title":"Epidemiology of hidradenitis suppurativa and its comorbid conditions","volume":"91","author":"Midgette B","year":"2024","unstructured":"Midgette B, Garg A. Epidemiology of hidradenitis suppurativa and its comorbid conditions. J Am Acad Dermatol. 2024, 91:S3-7. 10.1016\/j.jaad.2024.09.013","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2016.28.2.147","article-title":"Management of hidradenitis suppurativa in patients with metabolic comorbidities","volume":"28","author":"Lim ZV","year":"2016","unstructured":"Lim ZV, Oon HH. Management of hidradenitis suppurativa in patients with metabolic comorbidities. Ann Dermatol. 2016, 28:147-51. 10.5021\/ad.2016.28.2.147","journal-title":"Ann Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179716","article-title":"Immunomodulatory drugs in the treatment of hidradenitis suppurativa-possibilities and limitations","volume":"23","author":"\u015awierczewska Z","year":"2022","unstructured":"\u015awierczewska Z, Lewandowski M, Surowiecka A, Bara\u0144ska-Rybak W. Immunomodulatory drugs in the treatment of hidradenitis suppurativa-possibilities and limitations. Int J Mol Sci. 2022, 23:9716. 10.3390\/ijms23179716","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2025.10328","article-title":"Hidradenitis suppurativa: state-of-the-art review and update","author":"Virone M","year":"2025","unstructured":"Virone M, Zappia E, Di Caro A, et al.. Hidradenitis suppurativa: state-of-the-art review and update. Dermatol Reports. 2025, 10.4081\/dr.2025.10328","journal-title":"Dermatol Reports"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12144847","article-title":"Investigating adiposity-related metabolic health phenotypes in patients with hidradenitis suppurativa: a cross-sectional study","volume":"12","author":"Mintoff D","year":"2023","unstructured":"Mintoff D, Agius R, Fava S, Pace NP. Investigating adiposity-related metabolic health phenotypes in patients with hidradenitis suppurativa: a cross-sectional study. J Clin Med. 2023, 12:4847. 10.3390\/jcm12144847","journal-title":"J Clin Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2015.08.004","article-title":"Inflammatory mechanisms in hidradenitis suppurativa","volume":"34","author":"Kelly G","year":"2016","unstructured":"Kelly G, Prens EP. Inflammatory mechanisms in hidradenitis suppurativa. Dermatol Clin. 2016, 34:51-8. 10.1016\/j.det.2015.08.004","journal-title":"Dermatol Clin"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac107","article-title":"Adipokines as an important link between hidradenitis suppurativa and obesity: a narrative review","volume":"188","author":"Krajewski PK","year":"2023","unstructured":"Krajewski PK, Matusiak \u0141, Szepietowski JC. Adipokines as an important link between hidradenitis suppurativa and obesity: a narrative review. Br J Dermatol. 2023, 188:320-7. 10.1093\/bjd\/ljac107","journal-title":"Br J Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11154358","article-title":"Macrophages, low-grade inflammation, insulin resistance and hyperinsulinemia: a mutual ambiguous relationship in the development of metabolic diseases","volume":"11","author":"P\u00fcschel GP","year":"2022","unstructured":"P\u00fcschel GP, Klauder J, Henkel J. Macrophages, low-grade inflammation, insulin resistance and hyperinsulinemia: a mutual ambiguous relationship in the development of metabolic diseases. J Clin Med. 2022, 11:4358. 10.3390\/jcm11154358","journal-title":"J Clin Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/479354","article-title":"Insulin resistance and skin diseases","volume":"2015","author":"Napolitano M","year":"2015","unstructured":"Napolitano M, Megna M, Monfrecola G. Insulin resistance and skin diseases. ScientificWorldJournal. 2015, 2015:479354. 10.1155\/2015\/479354","journal-title":"ScientificWorldJournal"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.110753","article-title":"Role of insulin resistance and diet in acne","volume":"79","author":"Kumari R","year":"2013","unstructured":"Kumari R, Thappa DM. Role of insulin resistance and diet in acne. Indian J Dermatol Venereol Leprol. 2013, 79:291-9. 10.4103\/0378-6323.110753","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S90662","article-title":"SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin","volume":"8","author":"Seufert J","year":"2015","unstructured":"Seufert J. SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes Metab Syndr Obes. 2015, 8:543-54. 10.2147\/DMSO.S90662","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie MR","year":"2020","unstructured":"Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020, 17:761-72. 10.1038\/s41569-020-0406-8","journal-title":"Nat Rev Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1590\/2175-8239-JBN-2023-0187en","article-title":"SGLT2 inhibitors and NLRP3 inflammasome: potential target in diabetic kidney disease","volume":"46","author":"Machado J\u00fanior PA","year":"2024","unstructured":"Machado J\u00fanior PA, Lass A, Pilger BI, Fornazari R, Moraes TP, Pinho RA. SGLT2 inhibitors and NLRP3 inflammasome: potential target in diabetic kidney disease. J Bras Nefrol. 2024, 46:e20230187. 10.1590\/2175-8239-JBN-2023-0187en","journal-title":"J Bras Nefrol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v16.i7.107335","article-title":"Sodium-glucose co-transporter 2 inhibitors improve insulin resistance and \u03b2-cell function in type 2 diabetes: a meta-analysis","volume":"16","author":"Chai SY","year":"2025","unstructured":"Chai SY, Zhang RY, Ning ZY, Zheng YM, Swapnil R, Ji LN. Sodium-glucose co-transporter 2 inhibitors improve insulin resistance and \u03b2-cell function in type 2 diabetes: a meta-analysis. World J Diabetes. 2025, 16:107335. 10.4239\/wjd.v16.i7.107335","journal-title":"World J Diabetes"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20797","article-title":"Comparative effect of metformin and SGLT2i on vascular risk and mortality in hidradenitis suppurativa","volume":"39","author":"Gotor-Rivera A","year":"2025","unstructured":"Gotor-Rivera A, Hern\u00e1ndez-S\u00e1nchez J, Chamorro-Jim\u00e9nez E, Garc\u00eda-Rivera E, Ortiz-Romero P, Rivera-Diaz R. Comparative effect of metformin and SGLT2i on vascular risk and mortality in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2025, 39:e1025-8. 10.1111\/jdv.20797","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim SR","year":"2020","unstructured":"Kim SR, Lee SG, Kim SH, et al.. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020, 11:2127. 10.1038\/s41467-020-15983-6","journal-title":"Nat Commun"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26041670","article-title":"Anti-inflammatory effects of SGLT2 inhibitors: focus on macrophages","volume":"26","author":"Rykova EY","year":"2025","unstructured":"Rykova EY, Klimontov VV, Shmakova E, Korbut AI, Merkulova TI, Kzhyshkowska J. Anti-inflammatory effects of SGLT2 inhibitors: focus on macrophages. Int J Mol Sci. 2025, 26:1670. 10.3390\/ijms26041670","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228436","article-title":"Cytokine pathways and investigational target therapies in hidradenitis suppurativa","volume":"21","author":"Del Duca E","year":"2020","unstructured":"Del Duca E, Morelli P, Bennardo L, Di Raimondo C, Nistic\u00f2 SP. Cytokine pathways and investigational target therapies in hidradenitis suppurativa. Int J Mol Sci. 2020, 21:8436. 10.3390\/ijms21228436","journal-title":"Int J Mol Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad184","article-title":"Targeting the NLRP3 inflammasome reduces inflammation in hidradenitis suppurativa skin","volume":"189","author":"Moran B","year":"2023","unstructured":"Moran B, Smith CM, Zaborowski A, et al.. Targeting the NLRP3 inflammasome reduces inflammation in hidradenitis suppurativa skin. Br J Dermatol. 2023, 189:447-58. 10.1093\/bjd\/ljad184","journal-title":"Br J Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.11.014","article-title":"The prevalence of metabolic syndrome in patients with hidradenitis suppurativa","volume":"70","author":"Gold DA","year":"2014","unstructured":"Gold DA, Reeder VJ, Mahan MG, Hamzavi IH. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2014, 70:699-703. 10.1016\/j.jaad.2013.11.014","journal-title":"J Am Acad Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14894","article-title":"Insulin resistance in hidradenitis suppurativa: a case-control study","volume":"32","author":"Vilanova I","year":"2018","unstructured":"Vilanova I, Hern\u00e1ndez JL, Mata C, et al.. Insulin resistance in hidradenitis suppurativa: a case-control study. J Eur Acad Dermatol Venereol. 2018, 32:820-4. 10.1111\/jdv.14894","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01458.x","article-title":"Critical role of the interleukin-23\/T-helper 17 cell axis in the pathogenesis of psoriasis","volume":"39","author":"Nakajima K","year":"2012","unstructured":"Nakajima K. Critical role of the interleukin-23\/T-helper 17 cell axis in the pathogenesis of psoriasis. J Dermatol. 2012, 39:219-24. 10.1111\/j.1346-8138.2011.01458.x","journal-title":"J Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2022.11124","article-title":"Update on the etiopathogenesis of psoriasis (review)","volume":"23","author":"Branisteanu DE","year":"2022","unstructured":"Branisteanu DE, Cojocaru C, Diaconu R, et al.. Update on the etiopathogenesis of psoriasis (review). Exp Ther Med. 2022, 23:201. 10.3892\/etm.2022.11124","journal-title":"Exp Ther Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-025-02271-y","article-title":"NLRP3-inflammasome related genes as emerging biomarkers and therapeutic targets in psoriasis","volume":"48","author":"Shi A","year":"2025","unstructured":"Shi A, Shu Y, Hu K, Sudesh S, Tu Y. NLRP3-inflammasome related genes as emerging biomarkers and therapeutic targets in psoriasis. Inflammation. 2025, 48:3366-78. 10.1007\/s10753-025-02271-y","journal-title":"Inflammation"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70118","article-title":"Blockade of cannabinoid CB(1) receptors potentiates the anti-fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy","volume":"182","author":"Pointeau O","year":"2025","unstructured":"Pointeau O, Ba AI, Geissler A, et al.. Blockade of cannabinoid CB(1) receptors potentiates the anti-fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy. Br J Pharmacol. 2025, 182:5355-77. 10.1111\/bph.70118","journal-title":"Br J Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s44446-025-00039-x","article-title":"Therapeutic potential of canagliflozin in DEN\/TAA-induced renal cancer: mechanistic insights into NLRP3\/IL-6\/STAT3 and AMPK signaling and oxidative stress regulation","volume":"33","author":"Abdel-Rahman RF","year":"2025","unstructured":"Abdel-Rahman RF, Alsugoor MH, ALuhaymi N, Fayed HM, Mahmoud SS, Ibrahim FA, Elbaset MA. Therapeutic potential of canagliflozin in DEN\/TAA-induced renal cancer: mechanistic insights into NLRP3\/IL-6\/STAT3 and AMPK signaling and oxidative stress regulation. Saudi Pharm J. 2025, 33:38. 10.1007\/s44446-025-00039-x","journal-title":"Saudi Pharm J"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03406-y","article-title":"The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation","volume":"398","author":"Ridha-Salman H","year":"2025","unstructured":"Ridha-Salman H, Al-Zubaidy AA, Abbas AH, Hassan DM, Malik SA. The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation. Naunyn Schmiedebergs Arch Pharmacol. 2025, 398:2695-715. 10.1007\/s00210-024-03406-y","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt CH","year":"2017","unstructured":"Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017, 3:17011. 10.1038\/nrdp.2017.11","journal-title":"Nat Rev Dis Primers"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/srep44127","article-title":"Double-stranded RNA induces inflammation via the NF-\u03baB pathway and inflammasome activation in the outer root sheath cells of hair follicles","volume":"7","author":"Shin JM","year":"2017","unstructured":"Shin JM, Choi DK, Sohn KC, et al.. Double-stranded RNA induces inflammation via the NF-\u03baB pathway and inflammasome activation in the outer root sheath cells of hair follicles. Sci Rep. 2017, 7:44127. 10.1038\/srep44127","journal-title":"Sci Rep"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14432","article-title":"NLRP3 inflammasome activation contributes to development of alopecia areata in C3H\/HeJ mice","volume":"31","author":"Hashimoto K","year":"2022","unstructured":"Hashimoto K, Yamada Y, Sekiguchi K, Mori S, Matsumoto T. NLRP3 inflammasome activation contributes to development of alopecia areata in C3H\/HeJ mice. Exp Dermatol. 2022, 31:133-42. 10.1111\/exd.14432","journal-title":"Exp Dermatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27773","article-title":"Fournier\u2019s gangrene: a coexistence or consanguinity of SGLT-2 inhibitor therapy","volume":"14","author":"Chowdhury T","year":"2022","unstructured":"Chowdhury T, Gousy N, Bellamkonda A, et al.. Fournier\u2019s gangrene: a coexistence or consanguinity of SGLT-2 inhibitor therapy. Cureus. 2022, 14:e27773. 10.7759\/cureus.27773","journal-title":"Cureus"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2017.10.031","article-title":"Presentation and diagnosis of Fournier gangrene","volume":"114","author":"Voelzke BB","year":"2018","unstructured":"Voelzke BB, Hagedorn JC. Presentation and diagnosis of Fournier gangrene. Urology. 2018, 114:8-13. 10.1016\/j.urology.2017.10.031","journal-title":"Urology"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2019.10.029","article-title":"Safety of sodium-glucose co-transporter 2 inhibitors","volume":"124","author":"McGill JB","year":"2019","unstructured":"McGill JB, Subramanian S. Safety of sodium-glucose co-transporter 2 inhibitors. Am J Cardiol. 2019, 124:S45-52. 10.1016\/j.amjcard.2019.10.029","journal-title":"Am J Cardiol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10092036","article-title":"SGLT2 inhibitors, what the emergency physician needs to know: a narrative review","volume":"10","author":"Lu H","year":"2021","unstructured":"Lu H, Lu H, Kosinski C, et al.. SGLT2 inhibitors, what the emergency physician needs to know: a narrative review. J Clin Med. 2021, 10:2036. 10.3390\/jcm10092036","journal-title":"J Clin Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14010188","article-title":"Cutaneous adverse drug reactions associated with SGLT2 inhibitors","volume":"14","author":"Mederle AL","year":"2024","unstructured":"Mederle AL, Dumitrescu P, Borza C, Kundnani NR. Cutaneous adverse drug reactions associated with SGLT2 inhibitors. J Clin Med. 2024, 14:188. 10.3390\/jcm14010188","journal-title":"J Clin Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/491997-sodium-glucose-cotransporter-2-sglt2-inhibitors-as-therapy-for-hidradenitis-suppurativa-and-other-inflammatory-skin-diseases-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T03:32:47Z","timestamp":1780543967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/491997-sodium-glucose-cotransporter-2-sglt2-inhibitors-as-therapy-for-hidradenitis-suppurativa-and-other-inflammatory-skin-diseases-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":36,"URL":"https:\/\/doi.org\/10.7759\/cureus.110202","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,3]]}}}